Phase 2a Trial to Investigate the Efficacy of LIB-01 in Treatment of Erectile Dysfunction

Last updated: November 21, 2024
Sponsor: Dicot AB
Overall Status: Active - Recruiting

Phase

2

Condition

Erectile Dysfunction

Impotence

Infertility

Treatment

LIB-01 Placebo

LIB-01

Clinical Study ID

NCT06703840
DCT4564
  • Ages 25-65
  • Male

Study Summary

The goal of this clinical trial is to learn if the drug LIB-01 works to treat erectile dysfunction in male adults. It will also learn about the safety of the drug LIB-01. The main questions it aims to answer are:

  • Does the drug LIB-01 improve erectile function in males with erectile dysfunction?

  • What medical problems do participants have when taking the drug LIB-01? Researchers will compare the drug LIB-01 to a placebo (a look-alike substance that contains no drug) to see if the drug LIB-01 works to treat erectile dysfunction.

Participants will:

  • Take the drug LIB-01 or a placebo every day for 3 days

  • Visit the clinic every week for 4 weeks, and at 8 weeks, for checkups and tests

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Provision of signed and dated written informed consent prior to any trial specificprocedures.

  2. Male participant aged 25 to 65 years, inclusive, at the screening visit.

  3. In a stable heterosexual relationship for at least 6 months prior to the screeningvisit.

  4. Total score of 11-25 on questions 1-5 and 15 on the EF domain of the IIEFquestionnaire.

  5. Highly motivated to obtain treatment for ED.

  6. Willing to abstain from unprotected sex and use condom to prevent drug exposure of apartner and pregnancy from first dose until the end-of-trial. In addition, refrainfrom donating sperm from the date of dosing until 3 months after (last) dosing withthe IMP. Any female partner of child-bearing potential of a non-vasectomised trialparticipant must use contraceptive methods with a failure rate of < 1% to preventpregnancy until the end-of-trial visit.

  7. Understands the trial requirements.

Exclusion

Exclusion Criteria:

  1. History of any clinically significant disease or disorder, including psychiatricdisorder, which, in the opinion of the Investigator, may either put the participantat risk because of participation in the trial, or influence the results or theparticipant's ability to participate in the trial.

  2. Type 1 diabetes.

  3. Haemoglobin A1c (HbA1c) ≥48 mmol/L (6.5%).

  4. Any clinically significant illness, medical/surgical procedure or trauma within 4weeks of the first administration of IMP.

  5. Malignancy within the past 5 years, with the exception of in situ removal of basalcell carcinoma.

  6. Any planned major surgery within the duration of the trial.

  7. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, asjudged by the Investigator, or history of hypersensitivity to drugs with a similarchemical structure or class to LIB-01 API.

  8. History of priapism, or increased risk due to underlying illness, including but notlimited to hemoglobinopathies such as sickle cell anaemia or thalassemia.

  9. History of glaucoma.

  10. History of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).

  11. History of prostatectomy.

  12. History of alcohol abuse or excessive intake of alcohol, as judged by theInvestigator.

  13. Presence or history of drug abuse, as judged by the Investigator.

  14. History of, or current use of anabolic steroids, as judged by the Investigator.

  15. Bleeding deficiencies or ongoing anticoagulant therapy that would put theparticipant at risk, as judged by the investigator.

  16. Uncontrolled cardiac disease within 6 months of screening, including but not limitedto uncontrolled hypertension; unstable angina; myocardial infarction orcerebrovascular accident.

  17. Use of nitrate medications within 14 days prior to the screening visit.

  18. Use of any drug with narrow therapeutic index or drugs that are sensitivesubstrates, strong inducers or strong inhibitors to CYP3A4 as well as substrates andinhibitors of OATP1B1 or sensitive to substrates to CYP2B6 in accordance with thelist provided (see Section 9.6.2.1).

  19. Use of oral, injectable, intra-urethral, or topical pro-erectile drugs orsupplements, including but not limited to PDE5-Is or prostaglandin E1, or use ofdevices for ED treatment, within 14 days prior to screening.

  20. Primary hypoactive sexual desire.

  21. Presence of penile anatomical abnormalities, such as penile fibrosis or Peyronie'sdisease, which would cause significantly impaired sexual performance, as judged bythe Investigator.

  22. Insufficient therapeutic effect when using PDE5-Is.

  23. History of, or ongoing antiandrogen treatment.

  24. Any positive result at the screening visit for serum hepatitis B surface antigen,hepatitis B and C antibodies and/or human immunodeficiency virus (HIV).

  25. Abnormal vital signs, laboratory test value or ECG of clinical significance, asjudged by the Investigator.

  26. Moderate to severe renal impairment with an eGFR (creatinine) ≤60 mL/min (revisedMalmö-Lund equation).

  27. Moderate to severe hepatic impairment at the time of the screening visit, as judgedby the Investigator.

  28. Plasma donation within one month of screening or blood donation (or correspondingblood loss) during the last three months prior to the screening visit.

  29. Planned treatment or treatment with another investigational therapy (i.e., smallmolecule or biologic) within 3 months prior to the screening visit.

  30. Involvement in the planning, and/or conduct of the trial.

  31. The Investigator considers the participant unlikely to comply with trial procedures,restrictions and requirements.

Study Design

Total Participants: 140
Treatment Group(s): 2
Primary Treatment: LIB-01 Placebo
Phase: 2
Study Start date:
November 08, 2024
Estimated Completion Date:
June 30, 2025

Connect with a study center

  • Herlev Hospital

    Herlev, 2730
    Denmark

    Site Not Available

  • Clinical Trial Consultants

    Groningen, 9713 GZ
    Netherlands

    Active - Recruiting

  • Clinical Trial Consultants

    Mölndal, Göteborg 431 53
    Sweden

    Active - Recruiting

  • Clinical Trial Consultants

    Solna, Stockholm 171 64
    Sweden

    Active - Recruiting

  • Clinical Trial Consultants

    Linköping, 582 13
    Sweden

    Active - Recruiting

  • Clinical Trial Consultants

    Uppsala, 75237
    Sweden

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.